Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: In an observational study in a Turkish population

Helicobacter

Volumn 12, Issue 5, 2007, Pages 518-522

  Sezgin, Orhan ^a   Altintaş, Engin ^a   Üçbilek, Enver ^a   Tombak, Anil ^a   Tellioǧlu, Burçin ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Eradication treatment; Helicobacter pylori; Moxifloxacin

Indexed keywords

AMOXICILLIN; MOXIFLOXACIN; PANTOPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FUNCTION TEST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PEPTIC ULCER; PILOT STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TURKEY (REPUBLIC);

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PILOT PROJECTS; QUINOLINES; TREATMENT OUTCOME; TURKEY;

HELICOBACTER PYLORI;

EID: 34548209819     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00535.x     Document Type: Article

References (40)

1. Logan RPH, Walker MM. Epidemiology and diagnosis of Helicobacter pylori infection. BMJ 2001 323 : 920 2.
2. Sipponen P, Hyvarinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol 1993 28 (Suppl 196 3 6.
3. Stolte M, Edit S. Healing gastric MALT lymphoma by eradication of H. pylori. Lancet 1993 342 : 568.
4. Akin L, Tezcan S, Hasçelik G, Çakir B. Seroprevalence and some correlates of Helicobacter pylori at adult ages in Gülveren Health District, Ankara, Turkey. Epidemiol Infect 2004 132 : 847 56.
5. Özden A, Dumlu Ş, Dönderici Ö, Çetinkaya H, Soylu K, Özkan H. Helicobacter pylori infeksiyonunun ülkemizde seroepidemiyolojisi (H. pylori seroepidemiology in Turkey). Gastroenteroloji 1992 3 : 664 8.
6. Karaaslan H, Bektaş M, Soykan İ, Bahar K, Özden A. Türkiyede gönüllü kan donörlerinde Helicobacter pylori seroprevelansi (H. pylori seroprevalence in blood donors). Turk J Gastroenterol 2003 Suppl SB.03/1.
7. Altintaş E, Sezgin O, Ulu O, Aydin Ö, et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004 10 : 1656 8.
8. Gümürdülü Y, Serin E, Özer B, Kayaselçuk F, Özşahin K, Coşar AM. Low rates for eradication of Helicobacter pylori with triple therapy for 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 2004 10 : 668 71.
9. Avşar E, Kaymakoǧlu S, Erzin Y, et al. Dispeptik hastalarda Hp eradikasyonunda 14 günlük ranitidin bizmut sitrat bazli tedavi ile lansoprazol bazli üçlü tedaviyi karşilaştiran çok merkezli, randomize, prospektif bir çalişma (A multicenter, randomised, prospective, comparative study for 14 days ranitidine bismuth citrate and lansoprazole based triple therapy in patients with dyspepsia for Helicobacter pylori eradication). Turk J Gastroenterol 2004 Suppl SB.10/1.
10. Önder GF, Aydin A, Doǧanavşargil B, et al. Hp infeksiyonunda pantoprazol, amoksisilin, klaritromisin kombinasyonu ile 1 ve 2 haftalik tedavilerin etkinliǧi (The effectiveness of one- and two-week pantoprazole, amoxicillin, clarithromycin combination treatments in Helicobacter pylori infection). Turk J Gastroenterol 2003 Suppl PB. 08/44.
11. Sivri B, Şimşek İ, Hülagu S, et al. The efficacy, safety and tolerability of pantoprazole based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. Curr Med Res Opin 2004 20 : 1301 7.
12. Güliter S, Kelet H, Özkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori? Turk J Gastroenterol 2005 16 : 29 33.
13. Uygun A, Yeşilova Z, Ateş Y, et al. Helicobacter pylori pozitif non-ülser dispepsili hastalarda Hp eradikasyon tedavisinde 14 ve 7 günlük lansoprazol, amoksisilin, klaritromisin tedavi protokollerinin karşilaştirilmasi (Comparison of 14- and 7-day lansoprazole, amoxicillin, clarithromycin treatment protocols in patients with Helicobacter pylori positive non-ulcer dyspepsia). Turk J Gastroenterol 2004 Suppl PB. 08/15.
14. Ertaş E, Tüzün A, Özden A. Helicobacter pylori pozitif fonksiyonel dispepside 7 ve 14 günlük pantoprazol, klaritromisin, amoksisilin kombinasyon tedavisinin eradikasyon etkinliǧinin ve eradikasyonun dispeptik semptomlar üzerine etkilerinin deǧerlendirilmesi (Effectiveness of 7- and 14-day pantoprazole, amoxicillin, clarithromycin combination treatments in Helicobacter pylori positive functional dyspepsia). Turk J Gastroenterol 2004 Sup pl PB. 08/18.
15. Uygun A, Kadayifçi A, Yeşilova Z, et al. Hp eradikasyonunda lansoprazol ve pantoprazol içeren üçlü rejimlerin etkinliǧinin karşilaştirilmasi (Comparison of effectiveness of lansoprazole and pantoprazole based triple therapy in Helicobacter pylori eradication). Turk J Gastroenterol 2003 (Suppl) PB. 08/33.
16. Ünsal B, Ekinci N, Altinay A, et al. Helicobacter pylorinin klirensinde üçlü tedavinin etkinliǧi (Efficacy of triple therapy in Helicobacter pylori eradication). Gastroenteroloji 1993 4 : 284 6.
17. Özer B, Coşar A, Serin E, et al. Helicobacter pylori tedavisinde bizmut içeren dörtlü tedavi rejimiyle düşük eradikasyon oranlari (Low eradication rates with bismuth based quadruple therapy in Helicobacter pylori treatment). Turk J Gastroenterol 2004 Sup pl PB. 08/39.
18. Ataseven H, Mar N, Bahçecioǧlu Hİ, et al. Hp eradikasyonunda 14 günlük ranitidin bizmut sitrat, doksisiklin, amoksisilin ile pantoprazol, doksisiklin, amoksisilin tedavilerinin karşilaştirilmasi (Comparison of 14-day ranitidine bismuth citrate, doxicicline, amoxicillin and pantoprazole, doxicicline, amoxicillin in Helicobacter pylori eradication). Turk J Gastroenterol 2004 Sup pl PB. 08/57.
19. Sezgin O, Altintaş E, Üçbilek E, Tataroǧlu C. Bismuth-based therapies for the first-step eradication of Helicobacter pylori. Turk J Gastroenterol 2006 17 : 90 93.
20. Bosques-Padilla FJ, Garza-Gonzalez E, Calderon-Lozano IE, reed-SanRoman G, Suarez MA, Valdovinos-Diaz MA. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment. Helicobacter 2004 9 : 417 21.
21. Di Caro S, Ojetti V, Zocco MA, Cremonini F, Bartolozzi F, Candelli M, Lupascu A, Nista EC, Cammarota G, Gasbarrini A. mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 16 : 527 32.
22. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Alim Pharmacol Ther 2005 21 : 1241 7.
23. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006 101 : 1985 90.
24. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 1339 43.
25. Sharara AI, Chaar HF, Racoubian E, Moukhachen O, Barada KA, Mourad FH, Araj GF. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004 9 : 255 60.
26. Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006 11 : 46 51.
27. Scwartz H, Krause R, Sahba B, et al. Triple versus dual therapy eradication of helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithyromycin, and/or amoxycillin in different dosing regimens. Am J Gastroenterol 1998 93 : 584 90.
28. Tursi A, Cammarato G, Montalto M, et al. Low-dose omeprazole plus clariythromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Aliment Pharmacol Ther 1996 10 : 285 8.
29. Spinzi GC, Bierty L, Bortoli A, et al. Comparison of omeprazole and lansoprazole in short term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998 12 : 433 8.
30. Labenz J, Stolte M, Peitz U, et al. One-week triple therapy with omeprazole, amoxycillin and clarithromycin or metranidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1996 10 : 207 10.
31. Biggard MA, Delchier JC, Riachi G, et al. One week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori infection in patients with non-ulcer dyspepsia: influence of dosage of amoxycillin and clarithromycin. Aliment Pharmacol Ther 1998 12 : 383 8.
32. Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş G. Detection of point mutation on 23S rRNA in H. pylori and clarithromycin resistance by PCR-RFLP in gastric biopsy specimens in Mersin. Turk J Gastroenterol 2006 17 (Suppl 1) SB. 07 /01.
33. Dumlu GŞ, Karakan T, Deǧertekin B, Doǧan İ, Görgül A, Ünal S. Efficacy of 14 days levofloxacin based triple therapy for Helicobacter pylori infection. Endoskopi 2004 15 : 54 59.
34. Kanat Ünler G, Göktürk S, Demir M, Akaya D, Akçaer Öztürk N, Gür G, Yilmaz U. Efficacy of levofloxacin in primary and refractory Helicobacter pylori infection. Turk J Gastroenterol 2006 17 (Suppl 1 PB. 02/27.
35. Bal K, Hatemi İ, Baysal B, Sayilir A. Efficacy of levofloxacin based combination in H. pylori second-line treatment. Turk J Gastroenterol 2006 17 (Suppl 1 PB. 02/24.
36. Sezer R, Kaymakoǧlu S, Çakaloǧlu Y, et al. Effect of omeprazole plus ciprofloxacin on healing of duodenal ulcer and clearance of Helicobacter pylori. Med Bull İstanbul 1995 28 : 10 14.
37. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039 gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997 40 : 639 51.
38. Miyachi M, Aoyama N, Shirusaka D, Miki I, Matsumoto Y, Azuma T. Primary levofloxacin-resistance and gyr-A/B mutations among Helicobacter pylori in Japan. Am J Gastroenterol 2006 101 : A120.
39. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline and amoxicillin based quadruple regimen in a culture-guided third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004 19 : 789 95.
40. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995 39 : 107 11.